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ABSTRACT
Vancomycin-resistant enterococci (VRE) have emerged as important nosocomial pathogens, initially in
the USA, but now also in Europe, where hospital outbreaks are being reported with increasing
frequency, although the incidence of VRE infections remains extremely low in most European countries.
The recently demonstrated in-human transmission of vancomycin resistance from VRE to methicillin-
resistant Staphylococcus aureus (MRSA) in two American patients underscores the potential danger of a
coexisting reservoir of both pathogens. As MRSA is already endemic in many European hospital
settings, prevention of endemicity with VRE seems relevant, but should be balanced against the costs
associated with the implementation of effective strategies. The presence of a large community reservoir
of VRE in Europe could hamper the feasibility of infection control strategies. Although the prevalence of
colonisation amongst healthy subjects has apparently decreased after the ban on avoparcin use in the
agricultural industry, a large proportion of admitted patients are still potential sources of VRE
transmission. With no risk profile available to identify these carriers, effective screening, followed by
barrier precautions for carriers, seems to be impossible. Recent studies, however, have suggested that
hospital outbreaks are almost exclusively caused by specific genogroups of VRE that can be
characterised phenotypically and genotypically (e.g., co-resistance to ampicillin and the presence of
the variant esp gene). Based on our own experience, we propose that VRE infection control programmes
should be restricted to patients colonised with these VRE strains. If such a strain is cultured from a
clinical sample, surveillance amongst contact patients is recommended and barrier precautions should
be implemented in the case of documented spread.
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INTRODUCTION
Enterococci are the most common aerobic Gram-
positive cocci in the bowel and lower female genital
tract flora of humans and animals. Initially thought
of asmerely harmless commensalmicroorganisms,
enterococci have emerged as significant human
pathogens, currently being the thirdmost common
nosocomial bloodstream pathogen in the USA [1].
Enterococcal infections occur predominantly in
patients with immunodeficiencies, either due to
their underlying illness or to immunosuppressive
therapy, and in patients with breaches in normal
defensive barriers, such as intravascular lines and
urinary catheters. It has been reported that 60% of
enterococcal infections are nosocomial, with half of
them occurring in intensive care units (ICUs), most
probably because of the selection of these organ-
isms by the use of broad-spectrum antibiotics, such
as cephalosporins, which lack enterococcal activity
[2,3].
Although Enterococcus faecalis has been reported
to be responsible for 80–90% of enterococcal
infections and Enterococcus faecium for 10–20%
[2–4], more recent studies have suggested that the
proportion of infections caused by E. faecium has
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increased [5]. Unfortunately, little is known about
the pathogenic mechanisms or virulence factors of
these microorganisms, or how the innate immune
system of the host recognises E. faecium. Never-
theless, the increasing relevance of enterococci as
nosocomial pathogens is at least partly explained
by their intrinsic resistance to antibiotic classes
(such as cephalosporins, anti-staphylococcal pen-
icillins, clindamycin and trimethoprim) and their
natural ability to acquire and exchange genetic
elements encoding antibiotic resistance. A striking
example of the latter is the development of
plasmid-mediated vancomcyin resistance.
The first patients infected with plasmid-medi-
ated vancomycin-resistant enterococci (VRE)
were reported from France and England in 1986
[6,7]. The most common phenotype of resistance
(vanA) is associated with acquired, inducible,
high-level resistance to both vancomycin (MIC >
32 mg ⁄L) and teicoplanin (MIC > 16 mg ⁄L), and
is carried on a transposon (Tn1546) that is
transferable to other susceptible enterococci by
conjugation. Several acquired glycopeptide-resist-
ant phenotypes have been characterised since
then, including vanB and the less common vanD,
vanE and vanG types [8]. The vanB phenotype,
which is chromosomally mediated, inducible and
transferable by conjugation, mediates inducible
resistance to vancomycin, but not to teicoplanin.
However, the development of teicoplanin resist-
ance occurs rapidly during antibiotic exposure
[9]. Enterococci harbouring vanC genes, such as
E. flavescens and E. gallinarum, are intrinsically
resistant to low levels of vancomycin (MIC values
of 8–16 mg ⁄L). Remarkably, vancomycin resis-
tance is more common in E. faecium than in
E. faecalis [5,10,11].
Since the initial descriptions, VRE (predomin-
antly the vanA phenotype) have emerged as
important nosocomial pathogens worldwide
[1,12–23]. The first VRE outbreaks in US hospitals
often resulted from dissemination of a single
strain, especially in ICUs and nephrology wards
[24–26]. Subsequently, inter-hospital spread of
VRE was observed [27,28], and the monoclonal
nature of outbreaks changed to outbreaks char-
acterised by multiple enterococcal strains, finally
leading to situations of polyclonal endemicity
[13,28–32].
For obvious reasons, the need to control this
nationwide nosocomial epidemic of VRE was
widely recognised. In 1996, the Hospital Infection
Control Practices Advisory Committee (HICPAC)
of the Centers for Disease Control and Prevention
developed guidelines for the prevention and
control of the spread of VRE. These recommen-
dations were stringent and comprehensive, inclu-
ding prudent use of vancomycin, education of
hospital staff, measures for early detection of VRE
in the microbiology laboratory and immediate
implementation of isolation precautions for VRE-
colonised patients [33]. Although many motives
favour an aggressive and maximal control of VRE,
some aspects frustrate correct application of the
guidelines (Table 1). Here, we discuss the clinical
implications of VRE and the possibilities and
dilemmas of infection control strategies.
CLINICAL IMPLICATIONS
Attributable mortality and length of stay
Despite the undisputed increased frequency of
nosocomial bloodstream infectionswithVRE in the
Table 1. Arguments for and against the implementation of infection control measures to limit the nosocomial spread of
vancomycin-resistant enterococci (VRE)
For Against
VRE infections have attributable mortality Associations between VRE infections and mortality only represent
the severity of the underlying illness and are not attributable to
vancomycin resistance per se
VRE infection increases healthcare costs Associations between VRE infections and increased healthcare
costs, again, only represent the severity of the underlying illness and
cannot be attributed to vancomycin resistance per se
Infection control measures are effective in
controlling the spread of VRE
Required precautions are stringent and unpleasant for patients and
healthcare workers, only successful if implemented on a large
scale, and the cost-efficacy of infection control measures has not
been demonstrated
Infection control measures can be targeted
to specificgenogroups of VRE that can be
recognised phenotypically (on antibiotic
susceptibility profiles) and genotypically
The existence of a large reservoir of VRE amongst healthy subjects
precludes the implementation of large-scale infection control
policies
VRE are a source of vanA for
Staphylococcus aureus
New and effective antibiotics will be developed in time
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USA, the clinical significance of enterococcal bac-
teraemia remains controversial [1]. Some have
suggested that VRE bacteraemia is not an inde-
pendent risk factor for patient mortality, but
simply a reflection of the severity of the illness.
Indeed, multiple risk factors, mostly related to the
severity of illness, for colonisation and infection
with VRE have been identified, including increas-
ing Acute Physiology and Chronic Health Evalu-
ation (APACHE) II score [18,34], extensive
antibiotic treatment [5,11,14,18,25,27,35–43], renal
failure [5,34,38,44], prolonged hospitalisa-
tion [11,25,34,36–38,40,42,43,45], comorbidity
[14,41,46] andproximity to aVRE carrier [13,14,35].
Unequivocal proof of attributable mortality of
a certain nosocomial infection is difficult to
establish. For VRE, most analyses evaluating
attributable mortality rates have been retrospec-
tive with different study designs. In nine of the
15 studies listed in Table 2, no differences in
clinical outcome were found between patients
infected with VRE and patients infected
with vancomycin-susceptible enterococci (VSE)
[10,18,36,43,44,50], whereas negative impacts on
survival in patients with VRE bacteraemia were
found in six studies [5,34,45,49]. The small
sample sizes, choice of comparators and differ-
ences in matching criteria may explain this
discrepancy. Furthermore, differences in entero-
coccal species and susceptibility to ampicillin
may also affect mortality risk. E. faecium, fre-
quently resistant to ampicillin, currently is most
often associated with nosocomial bacteraemia
and has been associated with higher mortality
than E. faecalis [5,24].
It may be concluded that VRE bacteraemia is
indeed a marker for severe illness, but is less clear
if vancomycin resistance in itself is associated
with attributable mortality.
Nevertheless, VRE bacteraemia was generally
found to be associated with excess length of stay,
ranging from 6 to 22 days (Table 2).
Healthcare cost
If the length of stay in an ICU or hospital, the
intensity of therapy and the expenses for antimi-
crobial therapy are indeed increased for patients
with VRE, the attributable cost of infection with
these organisms is likely to be high. Moreover, the
presence of resistant microorganisms may neces-
sitate implementation of infection control proce-
dures, which will also increase healthcare costs
[12,29,51–53]. Unfortunately, little is known about
healthcare costs related to infections caused by
antibiotic-resistant microorganisms or about the
cost-effectiveness of infection control measures.
In head-to-head comparisons of patients infec-
ted or colonised with VRE and patients infected
with VSE, VRE carriage and bacteraemia were
indeed associated with higher healthcare costs
and prolonged hospitalisation [40,42,48,49,51].
However, obvious associations between the sever-
ity of the underlying illness, prolonged length of
stay and increased risks of acquiring colonisation
or infection with resistant microorganisms may
easily lead to uncertainty. For example, patients
with VRE infections were associated with attrib-
utable ICU costs when compared with patients
without enterococcal infections, but no such
differences were found when patients with VRE
infections were compared with patients with VSE
infections [47]. In another study, VRE infections,
when compared with VSE infections, were asso-
ciated with increased hospitalisation costs for less
severely ill patients, but costs were similar for
VRE and VSE infections in patients with severe
underlying illness [38].
The implementation of infection control meas-
ures is costly, and unequivocal proof of cost-
effectiveness would be a strong argument for the
widespread use of such strategies. An infection
control programme including twice-weekly rectal
surveillance for the early identification of critic-
ally ill patients with VRE colonisation, followed
by isolation, appeared to be cost-effective [51].
However, as for methicillin-resistant Staphylococ-
cus aureus (MRSA) [54], cost-effectiveness may
only be applicable to high-prevalence situations,
and the costs of a ‘surveillance–identification–
isolation’ strategy relative to the costs of infec-
tions averted should be used to determine the
threshold of VRE prevalence for the institution of
routine surveillance [51]. Whether the prevention
of endemicity of VRE in a hospital by periodical
point-prevalence studies in high-risk wards, such
as haemodialysis units and ICUs, is cost-effective
remains to be determined.
Therapy
Enterococci are intrinsically resistant to multiple
antimicrobial agents, whereas other antibiotics,
such as vancomcyin, are not bactericidal at clin-
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ically achievable concentrations. E. faecium is
typically resistant to high-level penicillin and
ampicillin, and this type of resistance has been
reported as a significant predictor of therapy
failure [2,3,55]. Combination therapy of a cell-wall
agent plus an aminoglycoside has become the
standard of care for patients with enterococcal
endocarditis, but prevalences of high-level resist-
ance for aminoglycosides and ampicillin are
increasing [2,3,5,55], leaving glycopeptides as
the remaining class of active antibiotics.
Obviously, the emergence of enterococci with
high-level resistance to glycopeptides has further
complicated therapeutic options. Beneficial effects
of chloramphenicol and tetracycline in the treat-
ment of VRE bacteraemia have been reported, but
the development of resistance during treatment
has also been documented [11,56,57]. Nitrofurant-
oin is active against many strains of VRE, but its
use is limited to urinary tract infections [55].
Ciprofloxacin is bacteriostatic for enterococci and,
in combination with ampicillin or gentamicin,
bactericidal in vitro. However, in-vivo data are
lacking [55]. The newer quinolones, such as
moxifloxacin, clinafloxacin and sparfloxacin, pos-
sess better activity than ciprofloxacin against
enterococci and may offer additive value in the
case of VRE infections [58,59].
Two classes of antibiotic have been approved
specifically for the treatment of VRE infections:
streptogramins and oxazolidinones [60]. Qui-
nupristin ⁄dalfopristin is a novel, injectable strep-
togramin antibiotic with in-vitro bacteriostatic
activity against most Gram-positive bacteria.
However, the MIC90 for E. faecalis (16 mg ⁄L)
exceeds the maximum achievable serum concen-
trations of 11–12 mg ⁄L, making quinupristin ⁄dal-
fopristin inactive for E. faecalis [61].
Reported rates of quinupristin ⁄dalfopristin
resistance amongst E. faecium (also resistant to
vancomcyin) range from less than 10% [17,61] to
22% [34]. In addition, the emergence of resistance
in E. faecium has been documented during ther-
apy [17,61–63]. Clinical response rates with qui-
nupristin ⁄dalfopristin were 60–70% in patients
with bacteraemia. Clinical failures were more
common in patients with VRE endocarditis and
meningitis [37,61,64].
Linezolid belongs to the oxazolidinone antibi-
otics and binds to the 23S ribosomal RNA of the
50S subunit on the bacterial ribosome, thereby
interrupting protein synthesis [65]. Linezolid has
potent in-vitro activity against both vancomycin-
resistant E. faecalis and E. faecium and good
therapeutic efficacy for VRE bacteraemia in mice
[62]. Because of its high bioavailability, it can be
administered orally and parenterally in equal
doses [65]. The emergence of resistance has been
reported, especially in patients who receive pro-
longed courses of therapy. Susceptibility testing
has therefore been recommended [65,66].
The optimal antimicrobial therapy for VRE
infections is not yet known. In general, antibiotics
are selected according to demonstrated in-vitro
activity. Most vancomycin-resistant E. faecalis and
some E. faecium isolates are susceptible to
ampicillin. Therefore, ampicillin, combined with
gentamicin in the case of endocarditis, remains
the recommended therapy for infections caused
by such organisms. Although enterococci with
MIC values of 16 mg ⁄L for ampicillin are consid-
ered to be resistant according to NCCLS guide-
lines, it has been suggested that the combination
of high-dose ampicillin (18–30 g ⁄day) and an
aminoglycoside could be effective in patients
with endocarditis or persistent bacteraemia
caused by VRE strains with MIC values for
ampicillin of up to 64 mg ⁄L [19].
INFECTION CONTROL ISSUES
Detection
Clinical cultures with VRE only represent the tip
of the iceberg. It has been estimated that, for every
patient with VRE isolated from clinical cultures,
at least 10 other patients will be colonised [67,68].
Asymptomatic carriers may remain unnoticed for
long periods of time, facilitating the widespread
dissemination of VRE within populations. As
enterococci are not considered gastrointestinal
pathogens, focused surveillance for selective
isolation is necessary to determine the total size
of the iceberg.
Several microbiological screening methods
have been developed for VRE using stool speci-
mens, rectal swabs or perirectal swabs. Isolation
of VRE from heavily contaminated specimens,
such as faeces, can be hampered because the
growth of VRE is inhibited by the indigenous
intestinal flora, as has been shown in an in-vitro
anaerobic continuous-flow culture model [69].
Nevertheless, isolation rates of VRE from stool
specimens are generally higher than those from
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rectal swabs [67,70] and, in one small study,
perirectal swabs were equally sensitive as rectal
swabs for the detection of VRE colonisation [71].
Direct inoculation of rectal swabs on vanco-
mycin-containing agar plates for selective culti-
vation of VRE has been used in many
laboratories [72]. The use of solid media instead
of broth offers the advantage of a rapid assess-
ment of colony morphology but, unfortunately,
low densities of VRE may not be detected [67].
Detection can be optimised by inoculating faecal
samples or swabs in broth enrichment, such as
Enterococcosel broth with vancomycin and azt-
reonam, followed by subculture on agar plates
containing vancomycin. This method is, of
course, more time-consuming, but has been
recommended for surveillance cultures from
patients [67,70,73–75] and environmental surfa-
ces [76]. In one study, however, no advantage
was found with enrichment compared with
direct plating [77].
The concentration of vancomycin in selective
media directly influences the specificity and
sensitivity; low concentrations (4–6 mg ⁄L) have
low specificities due to the co-isolation of vanco-
mycin-intermediate susceptible enterococci and
non-enterococcal species, such as lactobacilli
[70,72,74]. Higher concentrations (‡ 16 mg ⁄L)
may result in suboptimal detection of vanC-
resistant enterococci, without masking the detec-
tion of vanA-resistant enterococci [72].
However, even with all these considerations,
the detection of VRE may remain problematic.
Obvious relapses of colonisation have been repor-
ted frequently and are at least partly due to the
limited sensitivity of VRE culture methods
[67,78]. ‘False negative’ culture results may reflect
a decrease in the quantity of VRE to an undetect-
able level rather than true eradication. Such
patients could, unjustly, be considered as non-
colonised. However, undetected faecal colonisa-
tion may still result in skin contamination, and
subsequent dissemination via person-to-person
contact within hospitals [16,67]. High rates of false
negative results with direct plating methods
could be overcome by repeated sampling [72].
HICPAC guidelines recommend that a previously
colonised patient can be considered to be non-
colonised after three consecutive negative cul-
tures obtained with at least a 1-week interval [33].
However, even three consecutive negative cul-
tures do not unequivocally prove the eradication
of VRE [79–81]. Therefore, guiding infection
control strategies on the criteria of three consecu-
tive negative cultures may lead to false interpret-
ation of the true colonisation status of a patient.
Sources and transmission
VRE in the USA
There is huge inter-hospital variation in the
prevalence of VRE worldwide, although most
infections and hospital outbreaks have occurred
in the USA. There, hospitalised patients, especi-
ally those treated in high-risk wards, such as ICUs
and haemodialysis wards, should be considered
as the largest reservoir of VRE. Recent studies,
however, have clearly shown that the epidemiol-
ogy of VRE is no longer restricted to hospital
settings, as patients from long-term care facilities
appear to be colonised with VRE with increasing
frequency [82–84]. Colonised residents of long-
term care facilities may therefore become import-
ant VRE reservoirs and pose a potential infection
control risk when admitted to an acute care
hospital.
The gastrointestinal tract and skin are the most
important sites of VRE colonisation. Intestinal
colonisation almost always precedes VRE bacter-
aemia [51,79,85], and appears to be the major
reservoir from which the spread of the organism
occurs in healthcare settings [78–80,86–89]. Skin
colonisation may also contribute to the dissemin-
ation of VRE and can be a source of intravascular
device-associated infections [67,85].
Temporarily contaminated hands of healthcare
workers are important vectors for the transmis-
sion of VRE amongst patients [50]. The process of
cross-transmission requires healthcare workers to
have contact with different patients, some of
whom are colonised with VRE, and involves
lapses in infection control. Therefore, contact rates
(or workload), the likelihood of contact with
already colonised patients (colonisation pressure),
the likelihood of subsequent contact with a non-
colonised patient and adherence to infection
control measures (most notably hand disinfec-
tion) are important variables in the dynamics of
colonisation [90].
The duration of hospitalisation, admittance to
an ICU and antibiotic use have been associated
with prolonged carriage of VRE [80,91]. Not all
antibiotic classes are equally effective in selecting
for VRE. Vancomycin and cephalosporins have
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been selected as independent risk factors in many
studies. In addition, treatment with anti-anaerobic
antibiotics has been repeatedly associated with
high-density VRE colonisation [67,92]. Interest-
ingly, vancomycin has repeatedly been identified
as a risk factor for VRE colonisation. However,
selecting the comparator in such analyses is
crucial [93]. In a meta-analysis, analysing the
risks of vancomycin therapy for VRE colonisation
and infection, the pooled odds ratio (OR) for
vancomycin use was 10.7 for studies that
employed a control group of patients with VSE
colonisation [94]. Studies using control patients
who were not limited to VSE colonisation
revealed a much weaker association (OR, 2.7),
which was completely eliminated when the ana-
lysis was limited to studies that also controlled for
the time at risk prior to the outcome. The
explanation for this bias is that treatment with
active antibiotics (such as vancomycin for VSE)
probably inhibits the growth of susceptible bac-
teria, thereby making exposure less frequent in
patients colonised with susceptible bacteria, and
thus overestimating the risk.
The eradication of VRE colonisation has not
(yet) been possible, although a combination of
oral bacitracin and doxycycline showed transient
efficacy [95,96]. In addition, suppression of gas-
trointestinal colonisation was achieved with
ramoplanin, although colonisation rates had
completely recovered by day 21 after the discon-
tinuation of therapy [97].
Sustained VRE colonisation amongst healthy
American subjects remains extremely rare,
although colonisation has been demonstrated in
the gastrointestinal tract of healthcare workers
and family members of patients [98]. In one study,
three patients admitted directly from the commu-
nity, and with no history of recent previous
hospitalisation, appeared to be colonised with
VRE upon admission. These findings suggest that
VRE colonisation may have persisted for long
periods of time after remote nosocomial acquisi-
tion, or that VRE colonisation had been acquired
from unidentified community sources [99].
Acquisition of VRE amongst healthy individuals
in the community, without previous hospitali-
sation, has only been observed once [100]. There-
fore, in the USA, reservoirs of VRE are present
predominantly in healthcare facilities and a
significant community reservoir of VRE has not
been demonstrated.
In addition to patients themselves, their inan-
imate contaminated environment may play a role
in the epidemiology of VRE. Contamination of
environmental surfaces or equipment has been
documented frequently in clinical and out-patient
settings [53,83,84,101–104]. Contact with such
surfaces may contaminate hands [105]. However,
the relative importance of environmental contam-
ination in epidemiology is unknown. In one
study, contamination occurred frequently, but
usually temporarily and with low bacterial
counts, suggesting that the environment was
more a recipient than a source for patient coloni-
sation [106]. Nevertheless, contamination of a
blood pressure cuff by one patient, followed by
acquired colonisation of the next patient treated in
that room with the same genotype of VRE, was
shown in the same study [106]. The exact role of
environmental contamination in epidemiology,
and thus the necessity to include enforced envi-
ronmental cleaning as an infection control meas-
ure, has not been determined.
VRE in Europe
The European epidemiology with respect to VRE
is almost completely opposite to the American
situation. In Europe, only a few nosocomial
outbreaks have been reported (although this
incidence is increasing) and incidences of nosoco-
mial infection are low. However, asymptomatic
carriage amongst healthy European individuals is
relatively common [12,37,107–112]. This large
reservoir of VRE amongst healthy subjects has
been associated with the prolonged use of the
vancomycin analogue, avoparcin, as a growth
promoter in the livestock industry. Indeed, VRE
colonisation rates are extremely high in pigs,
calves and turkeys [109,111–113], and VRE has
also been found, although at much lower rates, in
the faeces from cats and dogs [114,115], shellfish
[116], woodmice and badgers [117]. Individuals in
close contact with these animals showed higher
rates of VRE colonisation than did healthy sub-
jects without such contacts. In addition, genotyp-
ically identical transposons containing the vanA
gene have been demonstrated in enterococci from
animals and farmers, slaughterers and residents
[109]. The link between avoparcin use and the
existing community reservoir of VRE is further
supported by the absence of VRE colonisation
amongst farm animals and healthy citizens in the
USA, where glycopeptides have never been used
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as growth promoters for livestock [100,118,119].
Moreover, after the ban on avoparcin use in the
agricultural industry in the European Community
in 1997, the prevalence of VRE in broiler chickens
and healthy persons decreased in several Euro-
pean countries, including the Scandinavian coun-
tries, the Netherlands and Germany [120,121]. Of
note, however, are the high prevalences of VRE
which persisted in broiler and turkey carcasses in
Denmark and Norway after the ban [121,122], as
well as in Swedish sewage samples [123]. Whe-
ther the ban on avoparcin use in the agricultural
industry will completely eliminate the commu-
nity reservoir of VRE in Europe is not yet known.
All of these associations strongly suggest a causal
relationship between the antibiotic-driven selec-
tion of VRE in animals and subsequent spillover
into the human population. How should this
linkage be interpreted in view of the differences
between European and American epidemiology?
Molecular genotyping using amplified fragment
length polymorphism and multilocus sequence
typing has identified different genogroups of VRE
amongst humans and animals [124]. Interestingly,
vancomycin-resistant E. faecium isolates from pigs
and chickens belonged to a genetically identical
cluster as isolates from non-hospitalised humans
[110,125], supporting the transmission of strains
from animals to humans. Remarkably, strains
recovered from hospitalised patients and hospital
outbreaks in the USA, Europe and Australia
belonged to a distinct genetic lineage of E. faecium
[110,125]. Isolates belonging to this lineage were
characterised by ampicillin resistance and the
presence of the variant esp gene, encoding for an
enterococcal surface protein. Both characteristics
are almost completely absent in non-epidemic
human and animal isolates [125]. These prelimin-
ary findings suggest that a clonal lineage of
E. faecium, capable of surviving in hospital settings,
and selected because of resistance to ampicil-
lin and vancomycin, has emerged on several
continents. If true, this would at least partly
explain why VRE has emerged in American
hospitals without the presence of a community
reservoir.
Evaluation of infection control measures
The HICPAC guidelines for the prevention and
control of the spread of VRE focus on the prudent
use of vancomycin, education of hospital staff,
early detection of VRE in the microbiology labor-
atory and immediate implementation of isolation
precautions [33].
Several studies have confirmed the effective-
ness of the complete package of measures in
controlling nosocomial outbreaks [14,37,126,127],
and even in reducing endemic prevalence [30],
although complete eradication of VRE from a
hospital appears to be extremely difficult [29].
Moreover, an active infection control programme,
including surveillance cultures and the isolation
of infected patients, reduced the overall preval-
ence of VRE in 32 healthcare facilities in three US
states in 3 years from 2.2% to 0.5% [128].
Enhanced infection control measures, such as
weekly surveillance cultures, observation of
hand-washing practices and cohorting of patients
and nurses, also decreased the incidence of VRE
bacteraemia, antibiotic use and healthcare costs
[51,129]. However, despite the formulation of
guidelines and reports of successful interventions,
the incidence of VRE infections is still increasing
in the USA [1]. A simple explanation is that,
despite all the guidelines, endemicity persists
because of poor hand hygiene compliance [29]. It
may also be argued that control measures have
been implemented too late; the existing reservoir
of VRE within hospitals is now too large for
successful infection control. Moreover, the extra-
mural population of VRE carriers, especially those
situated in long-term care facilities, may have
created such a large influx of VRE [130] to render
even improved infection control measures inef-
fective. It is also possible that transmission occurs
via as yet unidentified routes that are insuffi-
ciently addressed in the current guidelines. For
example, long-term environmental contamination
could serve as a constant reservoir for transmis-
sion, and thus complete prevention of patient-to-
patient transmission would still not lead to a
decrease in colonisation originating from envi-
ronmental surfaces.
The level of infection control measures
required depends on the number of patients
admitted with VRE, their length of stay and the
baseline level of endemic prevalence. Increases
in these variables can only be compensated for
by large increases in barrier precautions. Mathe-
matical analysis of VRE endemicity within an
ICU setting has suggested that, considering the
epidemiological dynamics in this setting, a
mean endemic prevalence of 75% will be
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established if no infection control measures are
implemented. Owing to infection control meas-
ures (such as 50% compliance for hand disin-
fection and a relatively high cohorting level of
nurses to individual patients), the observed
mean endemic prevalence was found to be
36% [90]. According to this model, infection
control therefore reduced the endemic preval-
ence from 75% to 36%.
The relative importance of individual infection
control measures has not been determined,
although the effects of individual measures have
been evaluated in some studies.
Reducing the antibiotic pressure seems to be a
logical approach for the control of VRE, asmultiple
studies have identified antibiotic therapy as a risk
factor for acquisition. Changes in specific pre-
scriber practice in ICUs were associated with
decreased vancomycin use and VRE prevalence,
when compared with ICUs in which no unit-
specific changes had been implemented [131]. In
contrast, VRE prevalence increased steadily over a
10-year period, despite dramatic reductions in
cephalosporin use, without concomitant aggres-
sive infection control interventions [132]. A pro-
gramme combining the restricted use of
vancomycin, cephalosporins and clindamycin
and the use of gowns for VRE-colonised patients
was associated with a considerable decrease in
VRE prevalence [133].
The use of gowns in addition to gloves is
controversial. The use of gloves and gowns
helped to control a monoclonal VRE outbreak
[134], and protected against the acquisition of
VRE, especially in patients with long-term VRE
exposure [135]. In contrast, the universal use of
gloves and gowns was no better than glove use
only in preventing colonisation with VRE in an
endemic ICU setting [68]. Part of the success of
using gowns may, in fact, result from better
compliance with other infection control proce-
dures when gowns are required, probably be-
cause of enhanced awareness of transmission
dynamics [135].
Transfer of vanA to Staphylococcus aureus
Vancomycin is a crucial antibiotic for infections
caused by MRSA. Ever since enterococci devel-
oped plasmid-based resistance to vancomycin,
the genetic transfer of vancomcyin resistance to
MRSA has been feared. Indeed, the transfer of the
vanA gene from E. faecalis to S. aureus in colonised
mice was demonstrated in 1992 [136]. However,
until 2002, decreased susceptibility to vancomycin
in S. aureus was restricted to so-called vancomy-
cin-intermediate S. aureus isolates based on the
thickening of the staphylococcal cell wall, with
MIC values of 8 mg ⁄L [137].
The first isolate of vancomycin-resistant
S. aureus (VRSA) harbouring the vanA gene was
recovered from a catheter exit site and a foot ulcer
from a patient with diabetes, peripheral vascular
disease and chronic renal failure in 2002 in
Michigan, USA [138,139]. In addition to VRSA,
vancomycin-resistant E. faecaliswas cultured from
the foot, and vancomycin-susceptible MRSA had
been identified in earlier cultures. The patient had
been treated with multiple courses of antibiotics,
including vancomycin. The isolate contained
the enterococcal vanA gene, consistent with the
vancomycin MIC profile of 32 mg ⁄L, and the
mecA gene, which confers resistance to oxacillin.
The DNA sequences of vanA genes from VRSA
and VRE isolates were identical, and vancomycin-
susceptible MRSA and VRSA isolates were indis-
tinguishable by pulsed-field gel electrophoresis,
strongly suggesting that the vanA gene had
jumped from the enterococcal donor strain to
the patient’s MRSA strain [138]. The second
clinical isolate of VRSA was isolated a few months
later from a patient admitted to a hospital in
Pennsylvania, USA [140]. This second case
appeared to be epidemiologically unrelated to
the first case and, as both strains probably
resulted from conjugation events, additional
VRSA infections are to be expected.
CONCLUSION
VRE have emerged as important nosocomial
pathogens, initially in the USA, but hospital
outbreaks are also being reported with increasing
frequency in Europe. Reasons for the need to
control the spread of VRE include the probable
attributable mortality and increased healthcare
costs due to VRE infection. Nevertheless, the
incidence of VRE infections is still extremely low
in most European countries, and therefore the
need for control must be balanced against the
costs associated with the implementation of
effective strategies. However, the recently dem-
onstrated in-human transmission of vancomycin
resistance from VRE to MRSA underscores the
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potential danger of a coexisting reservoir of both
pathogens. As MRSA is already endemic in many
European hospitals, the prevention of VRE ende-
micity seems to be the only alternative.
The presence of a large community reservoir of
VRE in Europe could hamper the feasibility of
infection control strategies. Based on prevalence
studies, up to 5% of non-hospitalised humans
could be asymptomatically colonised with VRE in
some European countries. Although this percent-
age is apparently decreasing after the ban on
avoparcin use in the agricultural industry, it still
means that a large proportion of admitted
patients are potential sources for VRE transmis-
sion. With no risk profile available to identify
these carriers, effective screening, followed by
barrier precautions for carriers, will simply be
impossible. Recent studies, however, suggest that
hospital outbreaks are almost exclusively caused
by a specific genogroup of vancomcyin-resistant
E. faecium that can easily be characterised by
co-resistance to ampicillin and the presence of the
variant esp gene [125].
Based on our own experience, we propose
that VRE infection control programmes should
be restricted to patients colonised by esp-positive
VRE strains. Ampicillin resistance appears to be
a specific and sensitive marker for this geno-
group [141]. If such a strain is cultured from a
clinical sample, surveillance amongst contact
patients, in order to trace an outbreak as soon
as possible, is recommended. For the same
reason, it may be wise to perform point-preval-
ence studies, periodically, on high-risk wards,
such as ICUs and haemodialysis wards. We
suggest that patients who are found to be
colonised with such strains should be marked
in the hospital information system. Isolation
precautions for these patients should be contin-
ued, even when surveillance cultures have
become negative for VRE. As these patients
are often transferred between healthcare facilit-
ies, national and, possibly, international guide-
lines to control the spread of VRE should be
established.
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